Cannabis Dependency - Why It Is More Serious Than You Have Been Told

The normalisation problem

The cultural shift around cannabis over the past decade has been profound and largely positive in public health terms - greater openness about use, reduced criminalisation in many jurisdictions, and better research into both therapeutic applications and harms. But normalisation carries a cost. When a substance becomes widely accepted, the threshold at which people recognise their own use as problematic rises. Social permission expands. Warning signs that would prompt concern with other substances are absorbed into the category of ordinary behaviour.

The consequence, in clinical settings, is a pattern that has become familiar: people presenting with cannabis dependency that has been developing for years, often dismissed by their GP, minimised by their family, and rationalised by themselves as something well short of an addiction. The cultural narrative - that cannabis is natural, non-addictive, and at worst a mild habit - has done genuine harm to people who needed to be taken seriously much earlier.

What cannabis dependency actually is

Cannabis use disorder is recognised in both the DSM-5 and ICD-11, the two primary diagnostic frameworks used in clinical psychiatry. It is characterised by a pattern of cannabis use that causes significant impairment or distress, typically including tolerance (needing more to achieve the same effect), difficulty controlling use, continued use despite negative consequences, and withdrawal symptoms on cessation.

The primary psychoactive compound in cannabis - delta-9-tetrahydrocannabinol, or THC - acts on the brain's endocannabinoid system, which plays a regulatory role in mood, appetite, memory, pain processing, and reward. Chronic exposure to THC causes the endocannabinoid system to downregulate its own activity, producing a dependency state in which the brain functions below baseline in the absence of the drug. This is a real physiological adaptation, not a weakness of character.

The potency of commercially available cannabis has increased substantially over the past two decades. The average THC concentration in cannabis products in many markets has tripled or quadrupled since the 1990s. This matters clinically because higher-potency cannabis is associated with faster development of dependence, more severe withdrawal, and greater psychiatric risk.

Who becomes dependent

Research consistently finds that approximately 9% of people who use cannabis will develop dependence. That figure rises to around 17% among those who begin using in adolescence, and to approximately one in three among daily users. These are not trivial numbers - cannabis is one of the most widely used substances in the world, which means that cannabis use disorder affects a very large number of people in absolute terms, even if the proportion of users affected is lower than for alcohol or opioids.

Risk factors for dependence include early onset of use, daily or near-daily use, a family history of substance use disorder, co-occurring anxiety or depression, and a history of trauma. The relationship between cannabis and mental health conditions is bidirectional - cannabis use can precipitate or worsen anxiety and depression, and people with anxiety or depression are more likely to use cannabis heavily as a form of self-medication, each dynamic reinforcing the other.

Cannabis withdrawal is real

One of the most persistent myths about cannabis is that it does not produce a withdrawal syndrome. This claim was credible when it was first made, based on older, lower-potency cannabis and less sensitive research instruments. It is no longer credible. Cannabis withdrawal syndrome is well documented and was formally recognised in DSM-5 in 2013.

Symptoms typically begin within 24 to 72 hours of cessation and peak in the first week, though they may persist for two to three weeks in heavy, long-term users. They include:

• Irritability, anger, and aggression - often the most disruptive symptom for relationships
• Anxiety and restlessness
• Insomnia and vivid, disturbing dreams
• Decreased appetite and nausea
• Depressed mood
• Headaches, sweating, and physical discomfort

These symptoms are not life-threatening, but they are sufficiently uncomfortable to drive relapse in the majority of people attempting to stop without support. The insomnia component is particularly difficult - sleep disruption in the first two to three weeks of cannabis abstinence is one of the most commonly cited reasons for returning to use.

The mental health dimension

The relationship between cannabis and psychiatric illness is the most clinically significant aspect of cannabis dependency and the most frequently underestimated. The evidence linking heavy cannabis use - particularly high-potency THC cannabis used from adolescence - with psychosis is now robust. A 2019 study in The Lancet Psychiatry found that daily use of high-potency cannabis was associated with a fivefold increase in the risk of psychotic disorder compared to never-users.

The mechanisms are not fully understood but are thought to involve THC's disruption of dopamine signalling in the prefrontal cortex and limbic system - regions central to both reward processing and the regulation of thought. Cannabis-induced psychosis is a recognised clinical entity that, in some cases, does not fully resolve even after abstinence.

Beyond psychosis, heavy cannabis use is consistently associated with worsening anxiety and depression over time, despite the fact that many users report using cannabis specifically to relieve those symptoms. The short-term anxiolytic effect of cannabis is real; the medium and long-term effect on anxiety disorders in dependent users is typically one of worsening, as the anxiety baseline rises in tandem with tolerance.

Why cannabis dependency is often dismissed

People seeking help for cannabis dependency face a specific set of obstacles that users of other substances do not. GPs often lack training in cannabis use disorder and may not take presentations seriously. Families, having absorbed the cultural message that cannabis is harmless, may be sceptical that treatment is warranted. The person themselves, having heard repeatedly that cannabis is not addictive, may struggle to name their own experience accurately.

The absence of visible physical deterioration - cannabis does not typically produce the somatic signs of alcohol or opioid dependence - makes the problem less legible to those around the user. The harms tend to be subtler and slower: motivational impairment, cognitive dulling, social withdrawal, missed opportunities, relationship erosion. These are real harms, but they do not look like what people expect addiction to look like.

What treatment looks like

Cannabis use disorder responds to treatment, but it benefits from the same intensity of intervention as other substance dependencies. Brief interventions have limited evidence of efficacy in established dependence. Motivational interviewing - which addresses the ambivalence that is almost always present - is a useful component of treatment, but it works best in combination with a longer-term therapeutic programme rather than as a standalone approach.

Cognitive behavioural therapy adapted for cannabis use disorder addresses the automatic thoughts and coping strategies that sustain use, and helps people build a repertoire of responses to cravings and triggers. Where co-occurring depression, anxiety, or ADHD are present - which is frequently the case - these need concurrent treatment rather than sequential treatment. Waiting until someone has been abstinent before treating their anxiety, for example, is likely to produce early relapse driven by untreated symptoms.

Recovery from cannabis dependency is not dramatic in the way that recovery from opioids can be. The improvements tend to come gradually: returning clarity of thought, improved mood stability, better sleep, re-engagement with activities and relationships that the dependency crowded out. For many people, the gap between who they were before heavy cannabis use and who they became during it is only apparent in retrospect - which is one of the reasons the dependency was so difficult to see while it was happening.

About the author

Christopher Murray

Dip.C.Hyp · HPD · NLP · MNCH

Christopher Murray is a cognitive hypnotherapist, NLP practitioner, and author of The Confidence Reset. Co-founder of the Sansun Group, he works with high-functioning individuals internationally and advises families and clients navigating addiction treatment and rehabilitation across Asia.

chrismurrayhypnosis.com confidenceresetnow.com